NYSE:ABT - Abbott Laboratories Stock Price, Price Target & More

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories announced a quarterly dividend on Friday, June 8th. Shareholders of record on Friday, July 13th will be given a dividend of $0.28 per share on Wednesday, August 15th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.77%. The ex-dividend date of this dividend is Thursday, July 12th. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) issued its quarterly earnings results on Wednesday, July, 18th. The healthcare product maker reported $0.73 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.71 by $0.02. The healthcare product maker had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.71 billion. Abbott Laboratories had a return on equity of 15.19% and a net margin of 3.13%. The firm's revenue for the quarter was up 17.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.62 EPS. View Abbott Laboratories' Earnings History.

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, October, 17th 2018. View Earnings Estimates for Abbott Laboratories.

Abbott Laboratories issued an update on its FY18 earnings guidance on Wednesday, July, 18th. The company provided earnings per share (EPS) guidance of $2.85-2.91 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.86. Abbott Laboratories also updated its Q3 guidance to $0.73-0.75 EPS.

18 equities research analysts have issued 12 month target prices for Abbott Laboratories' shares. Their forecasts range from $64.00 to $80.00. On average, they expect Abbott Laboratories' share price to reach $69.75 in the next year. This suggests a possible upside of 10.2% from the stock's current price. View Analyst Ratings for Abbott Laboratories.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Media headlines about ABT stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Abbott Laboratories earned a media sentiment score of 0.12 on Accern's scale. They also assigned news stories about the healthcare product maker an impact score of 45.84 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Abbott Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.12%), Swedbank (0.09%), Retirement Systems of Alabama (0.09%), Atalanta Sosnoff Capital LLC (0.06%), Gateway Investment Advisers LLC (0.06%) and Cornerstone Wealth Management LLC (0.05%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Hartford Investment Management Co., Bank of Montreal Can, Stralem & Co. Inc., Palo Capital Inc., Deprince Race & Zollo Inc., Meag Munich Ergo Kapitalanlagegesellschaft MBH and Rathbone Brothers plc. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

ABT stock was purchased by a variety of institutional investors in the last quarter, including Swedbank, Cornerstone Wealth Management LLC, Atalanta Sosnoff Capital LLC, Dalton Greiner Hartman Maher & Co., Contravisory Investment Management Inc., Whittier Trust Co., State of Alaska Department of Revenue and Calamos Advisors LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Daniel J Starks, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $63.32.

Abbott Laboratories has a market capitalization of $111.82 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.